properdin
complement
amlitelimab
zanolimumab
intetumumab
seroimmunity
immunome
antiserum
active immunity
antiantibody
MYD88
glembatumumab
immunoprotein
immunoexpression
alloantibody
presentation
cytokine
antihuman
gamma globulin
human gamma globulin
namilumab
sonepcizumab
antigenomic
elotuzumab
tucotuzumab
soravtansine
bivatuzumab
ipilimumab
monospecific
immunosubunit
immunodeposition
carlumab
affinity
immunodeposit
agonistic monoclonal antibody
hematoimmune
talizumab
-lim-
secukinumab
immunocompetence
ocrelizumab
bursopentine
immunoexpress
sifalimumab
hyperimmunoglobulin
muromonab
intrabody
pathoantigen
vobarilizumab
immunoarchitecture
complementology
immunogen
immunoprecipitant
allotype
affibody
immunoadaptor
mavrilimumab
gimsilumab
immunoproteomics
immune privilege
immunology
immunopeptide
ruplizumab
immunoprecipitate
vepalimomab
-ab
olendalizumab
IgD
antisubstance
immunoreactant
tisotumab
-zumab
immunosystem
recognition
immunohistopathology
immunocytic
immunoresponsive
auto-immune
adjuvant
immunoantigen
paratope
envoplakin
immunoserum
immunoglobulin D
antigenic
immunoblotting
otilimab
microantibody
bispecific
onartuzumab
reagin
sirukumab
histocompatibility antigen
immunocompetent
faralimomab
immunoglobin
seroconversion